Status:
COMPLETED
Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors
Lead Sponsor:
Amgen
Collaborating Sponsors:
Takeda
Conditions:
Advanced Gastrointestinal Stromal Tumor
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
The purpose of the study is to evaluate the safety and efficacy of AMG 706 in patients with gastrointestinal stromal tumor that have not been controlled while taking imatinib mesylate.
Eligibility Criteria
Inclusion
- Diagnosis of histological confirmed GIST
- Had prior imatinib mesylate therapy
- Has at least 1 measurable leasion by modified RECIST
Exclusion
- Central nervous system tumor involvement requiring treatment
- History of myocardial infraction
- Uncontrolled hypertension
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00254267
Start Date
November 1 2005
End Date
December 1 2012
Last Update
February 27 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.